Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Wright

Showing results (151-160 of 195) with videos related to

Pageof 20
Sort By:
Journal of the American College of Cardiology|December 6, 2023
Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical TrialsR Scott Wright, Wolfgang Koenig, Ulf Landmesser, et al.
Journal of Critical Care|January 7, 2019
Severity of illness assessment with application of the APACHE IV predicted mortality and outcome trends analysis in an academic cardiac intensive care unitCourtney E Bennett, R Scott Wright, Jacob Jentzer, et al.
Atherosclerosis|March 6, 2024
Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level interventionKausik K Ray, Laura H Gunn, Lorena Garcia Conde, et al.
The Lancet. Diabetes & Endocrinology|January 9, 2023
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trialKausik K Ray, Roel P T Troquay, Frank L J Visseren, et al.
Mayo Clinic Proceedings|October 22, 2019
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 StudiesR Scott Wright, Michael G Collins, Robert M Stoekenbroek, et al.
Cardiovascular Research|May 16, 2024
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trialR Scott Wright, Frederick J Raal, Wolfgang Koenig, et al.
Journal of General Internal Medicine|June 3, 2022
Elements Influencing Recruitment and Retention of Millennial Hospitalists Born in or after 1982: a Survey-Based StudyAmteshwar Singh, Tiffani Panek, Sean Tackett, et al.
Annals of Internal Medicine|October 2, 2002
Acute myocardial infarction and renal dysfunction: a high-risk combinationR Scott Wright, Guy S Reeder, Charles A Herzog, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|July 20, 2018
Ethical Issues and Recommendations in Grateful Patient Fundraising and PhilanthropyMegan E Collins, Steven Rum, Jane Wheeler, et al.
Journal of the American Heart Association|November 18, 2016
Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS TrialBarbara E Stähli, Catherine Gebhard, Valérie Duchatelle, et al.
Pageof 20

Showing results (151-160 of 195) with videos related to

Sort By:
Pageof 20
Journal of the American College of Cardiology|December 6, 2023
Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical TrialsR Scott Wright, Wolfgang Koenig, Ulf Landmesser, et al.
Journal of Critical Care|January 7, 2019
Severity of illness assessment with application of the APACHE IV predicted mortality and outcome trends analysis in an academic cardiac intensive care unitCourtney E Bennett, R Scott Wright, Jacob Jentzer, et al.
Atherosclerosis|March 6, 2024
Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level interventionKausik K Ray, Laura H Gunn, Lorena Garcia Conde, et al.
The Lancet. Diabetes & Endocrinology|January 9, 2023
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trialKausik K Ray, Roel P T Troquay, Frank L J Visseren, et al.
Mayo Clinic Proceedings|October 22, 2019
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 StudiesR Scott Wright, Michael G Collins, Robert M Stoekenbroek, et al.
Cardiovascular Research|May 16, 2024
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trialR Scott Wright, Frederick J Raal, Wolfgang Koenig, et al.
Journal of General Internal Medicine|June 3, 2022
Elements Influencing Recruitment and Retention of Millennial Hospitalists Born in or after 1982: a Survey-Based StudyAmteshwar Singh, Tiffani Panek, Sean Tackett, et al.
Annals of Internal Medicine|October 2, 2002
Acute myocardial infarction and renal dysfunction: a high-risk combinationR Scott Wright, Guy S Reeder, Charles A Herzog, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|July 20, 2018
Ethical Issues and Recommendations in Grateful Patient Fundraising and PhilanthropyMegan E Collins, Steven Rum, Jane Wheeler, et al.
Journal of the American Heart Association|November 18, 2016
Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS TrialBarbara E Stähli, Catherine Gebhard, Valérie Duchatelle, et al.
Pageof 20